Improving pandemic H5N1 influenza vaccines by combining different vaccine platforms

References

• World Health Organization. Avian influenza: assessing the pandemic threat. 2005. Available from: www.who.int/influenza/resources/documents/h5n1_assessing_pandemic_threat/en/
   Google Scholar
• World Health Organization. Influenza (Seasonal) Fact Sheet. 2009. Available from: www.who.int/mediacentre/factsheets/fs211/en/
   Google Scholar
• Palese P, Shaw ML. Orthomyxoviridae: the viruses and their replication. In: Knipe DM, Howley PM, Griffin DE, et al. editors. Fields virology. Lippincott, Williams and Wilkins; Philadelphia, PA, USA: 2007. p. 1647-989
   Google Scholar
• Jagger BW, Wise HM, Kash JC, et al. An overlapping protein-coding region in influenza A virus segment 3 modulated the host response. Science 2012;337:199-204
   PubMed Web of Science ®Google Scholar
• Tong S, Li Y, Rivailler P, et al. A distinct lineage of influenza A virus from bats. Proc Natl Acad Sci USA 2012;109(11):4269-74
   PubMed Web of Science ®Google Scholar
• Tong S, Zhu X, Li Y, et al. New world bats harbor diverse influenza A viruses. PLoS Pathog 2013;9(10):e1003657
   PubMed Web of Science ®Google Scholar
• Johnson NP, Mueller J. Updating the accounts: global mortality of the 1918-1920 “Spanish” influenza pandemic. Bull Hist Med 2002;76(1):105-15
   Google Scholar
• Hancock K, Veguilla V, Lu X, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009;361(20):1945-52
   PubMed Web of Science ®Google Scholar
• O’Donnell CD, Wright A, Vogel LN, et al. Effect of priming with H1N1 influenza viruses of variable antigenic distances on challenge with 2009 pandemic H1N1 virus. J Virol 2012;86(16):8625-33
   PubMed Web of Science ®Google Scholar
• Dawood FS, Iuliano AD, Reed C, et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis 2012;12(9):687-95
   PubMed Web of Science ®Google Scholar
• Simonsen L, Spreeuwenberg P, Lustig R, et al. Global mortality estimates for the 2009 influenza pandemic from the GLaMOR project: a modeling study. PLoS Med 2013;10(11):e1001558
   PubMed Web of Science ®Google Scholar
• Belser JA, Bridges CB, Katz JM, Tumpey TM. Past, present, and possible future human infection with influenza virus A subtype H7. Emerg Infect Dis 2009;15(6):859-65
   PubMed Web of Science ®Google Scholar
• Neumann G, Chen H, Gao GF, et al. H5N1 influenza viruses: outbreaks and biological properties. Cell Res 2010;20(1):51-61
   PubMed Web of Science ®Google Scholar
• Peiris JS. Avian influenza viruses in humans. Rev Sci Tech Off Int Epiz 2009;28:161-74
   PubMed Web of Science ®Google Scholar
• Reperant LA, Kuiken T, Osterhaus AD. Influenza viruses: from birds to humans. Hum Vaccin Immunother 2012;8(1):7-16
   PubMed Web of Science ®Google Scholar
• Subbarao K, Katz J. Avian influenza viruses infecting humans. Cell Mol Life Sci 2000;57(12):1770-84
   PubMed Web of Science ®Google Scholar
• World Health Organization. 2014. Available from: www.who.int/influenza/human_animal_interface_/EN_GIP_20140124CumulativeNumberH5N1cases.pdf?ua=1
   Google Scholar
• World Health Organization. 2014. Available from: www.who.int/influenza/human_animal_interface/influenza/influenza_h7n9/Risk_Assessment/en
   Google Scholar
• Fiore AE, Bridges CB, Katz JM, Cox NJ. Inactivated influenza vaccines. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. Elsevier Saunders; Philadelphia, PA, USA: 2013. p. 257-93
   Google Scholar
• Luke CJ, Lakdawala SS, Subbarao K. Influenza vaccine - live. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. Elsevier Saunders; Philadelphia, PA, USA: 2013. p. 294-311
   Google Scholar
• Basha S, Hazenfeld S, Brady RC, Subbramanian RA. Comparison of antibody and T-cell responses elicited by licensed inactivated- and live-attenuated influenza vaccines against H3N2 hemagglutinin. Hum Immunol 2011;72(6):463-9
   PubMed Web of Science ®Google Scholar
• Clements ML, Betts RF, Tierney EL, Murphy BR. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol 1986;24:157-60
   PubMed Web of Science ®Google Scholar
• Clements ML, Murphy BR. Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine. J Clin Microbiol 1986;23:66-72
   PubMed Web of Science ®Google Scholar
• Forrest DB, Pride MW, Dunning AJ, et al. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol 2008;15:1042-53
   PubMed Web of Science ®Google Scholar
• He XS, Holmes TH, Zhang C, et al. Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol 2006;80:11756-66
   PubMed Web of Science ®Google Scholar
• Hoft DF, Babusis E, Worku S, et al. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis 2011;204(6):845-53
   PubMed Web of Science ®Google Scholar
• Lanthier PA, Huston GE, Moquin A, et al. Live attenuated influenza vaccine (LAIV) impacts innate and adaptive immune responses. Vaccine 2011;29(44):7849-56
   PubMed Web of Science ®Google Scholar
• Sasaki S, He XS, Holmes TH, et al. Influence of prior influenza vaccination on antibody and B-cell responses. PLoS One 2008;3:e2975
   PubMed Web of Science ®Google Scholar
• Sasaki S, Jaimes MC, Holmes TH, et al. Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines. J Virol 2007;81:215-28
   PubMed Web of Science ®Google Scholar
• Subbarao K, Matsuoka Y. The prospects and challenges of universal vaccines for influenza. Trends Microbiol 2013;21(7):350-8
   PubMed Web of Science ®Google Scholar
• Baz M, Luke CJ, Cheng X, et al. H5N1 vaccines in humans. Virus Res 2013;178(1):78-98
   PubMed Web of Science ®Google Scholar
• Couch RB, Patel SM, Wade-Bowers CL, Nino D. A randomized clinical trial of an inactivated avian influenza A (H7N7) vaccine. PLoS One 2012;7(12):e49704
   PubMed Web of Science ®Google Scholar
• Cox RJ, Madhun AS, Hauge S, et al. A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine 2009;27(13):1889-97
   PubMed Web of Science ®Google Scholar
• Hehme N, Engelmann H, Kunzel W, et al. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines. Med Microbiol Immunol 2002;191:203-8
   PubMed Web of Science ®Google Scholar
• World Health Organization. 2007. Available from: www.who.int/immunization/diseases/influenza/clinical_evaluation_tables/en/
   Google Scholar
• Luke CJ, Subbarao K. Vaccines for pandemic influenza. Emerg Infect Dis 2006;12:66-72
   PubMed Web of Science ®Google Scholar
• Subbarao K, Joseph T. Scientific barriers to developing vaccines against avian influenza viruses. Nat Rev Immunol 2007;7(4):267-78
   PubMed Web of Science ®Google Scholar
• Nicholson KG, Colegate AE, Podda A, et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001;357(9272):1937-43
   PubMed Web of Science ®Google Scholar
• Subbarao K, Chen H, Swayne D, et al. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology 2003;305(1):192-200
   PubMed Web of Science ®Google Scholar
• Webby RJ, Perez DR, Coleman JS, et al. Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines. Lancet 2004;363(9415):1099-103
   PubMed Web of Science ®Google Scholar
• Ehrlich HJ, Muller M, Oh HM, et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 2008;358(24):2573-84
   PubMed Web of Science ®Google Scholar
• Howard MK, Kistner O, Barrett PN. Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines. Biol Chem 2008;389(5):569-77
   PubMed Web of Science ®Google Scholar
• Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza AV. Abdel-Ghafar AN, Chotpitayasunondh T, et al. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 2008;358(3):261-73
   PubMed Web of Science ®Google Scholar
• World Health Organization. 2014. Available from: www.who.int/influenza/vaccines/virus/201402_h5h7h9h10_vaccinevirusupdate.pdf?ua=1
   Google Scholar
• Subbarao K, Klimov A, Katz J, et al. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 1998;279(5349):393-6
   PubMed Web of Science ®Google Scholar
• Stephenson I, Nicholson KG, Colegate A, et al. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 2003;21(15):1687-93
   PubMed Web of Science ®Google Scholar
• Stephenson I, Bugarini R, Nicholson KG, et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 2005;191(8):1210-15
   PubMed Web of Science ®Google Scholar
• Galli G, Hancock K, Hoschler K, et al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci USA 2009;106(19):7962-7
   PubMed Web of Science ®Google Scholar
• Khurana S, Coyle EM, Dimitrova M, et al. Heterologous prime–boost vaccination with MF59-adjuvanted H5 vaccines promotes antibody affinity maturation towards the hemagglutinin HA1 domain and broad H5N1 cross-clade neutralization. PLoS One 2014;9(4):e95496
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Campbell JD, Zangwill KM, et al. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006;354(13):1343-51
   PubMed Web of Science ®Google Scholar
• Zangwill KM, Treanor JJ, Campbell JD, et al. Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans. J Infect Dis 2008;197(4):580-3
   PubMed Web of Science ®Google Scholar
• Belshe RB, Frey SE, Graham I, et al. Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant. J Infect Dis 2011;203(5):666-73
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Wilkinson BE, Masseoud F, et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 2001;19(13-14):1732-7
   PubMed Web of Science ®Google Scholar
• Ehrlich HJ, Muller M, Fritsch S, et al. A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses. J Infect Dis 2009;200(7):1113-18
   PubMed Web of Science ®Google Scholar
• Lin J, Zhang J, Dong X, et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 2006;368(9540):991-7
   PubMed Web of Science ®Google Scholar
• Lin JT, Li CG, Wang X, et al. Antibody persistence after 2-dose priming and booster response to a third dose of an inactivated, adjuvanted, whole-virion H5N1 vaccine. J Infect Dis 2009;199(2):184-7
   PubMed Web of Science ®Google Scholar
• Tambyah PA, Wilder-Smith A, Pavlova BG, et al. Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine. Vaccine 2012;30(2):329-35
   PubMed Web of Science ®Google Scholar
• van der Velden MV, Aichinger G, Pollabauer EM, et al. Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming. Vaccine 2012;30(43):6127-35
   PubMed Web of Science ®Google Scholar
• Dalmia N, Ramsay AJ. Prime–boost approaches to tuberculosis vaccine development. Expert Rev Vaccines 2012;11(10):1221-33
   PubMed Web of Science ®Google Scholar
• Hill AV, Reyes-Sandoval A, O’Hara G, et al. Prime–boost vectored malaria vaccines: progress and prospects. Hum Vaccin 2010;6(1):78-83
   PubMed Web of Science ®Google Scholar
• Paris RM, Kim JH, Robb ML, Michael NL. Prime–boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1. Expert Rev Vaccines 2010;9(9):1055-69
   PubMed Web of Science ®Google Scholar
• Goji NA, Nolan C, Hill H, et al. Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant. J Infect Dis 2008;198(5):635-41
   PubMed Web of Science ®Google Scholar
• Asmuth DM, Brown EL, DiNubile MJ, et al. Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime–boost regimens. J Infect Dis 2010;201(1):132-41
   PubMed Web of Science ®Google Scholar
• Koff WC, Russell ND, Walport M, et al. Accelerating the development of a safe and effective HIV vaccine: HIV vaccine case study for the Decade of Vaccines. Vaccine 2013;31(Suppl 2):B204-208
   Google Scholar
• Koup RA, Roederer M, Lamoreaux L, et al. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS One 2010;5(2):e9015
   Web of Science ®Google Scholar
• Smith LR, Wloch MK, Ye M, et al. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Vaccine 2010;28(13):2565-72
   PubMed Web of Science ®Google Scholar
• Wei CJ, Boyington JC, McTamney PM, et al. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 2010;329(5995):1060-4
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, Wei CJ, Hu Z, et al. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis 2011;11(12):916-24
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, Zephir K, Hu Z, et al. Prime–boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect. J Infect Dis 2013;208(3):418-22
   PubMed Web of Science ®Google Scholar
• Khurana S, Wu J, Dimitrova M, et al. DNA priming prior to inactivated influenza A(H5N1) vaccination expands the antibody epitope repertoire and increases affinity maturation in a boost-interval-dependent manner in adults. J Infect Dis 2013;208(3):413-17
   PubMed Web of Science ®Google Scholar
• Murphy BR, Coelingh K. Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines. Viral Immunol 2002;15:295-323
   PubMed Web of Science ®Google Scholar
• Karron RA, Talaat K, Luke C, et al. Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults. Vaccine 2009;27(36):4953-60
   PubMed Web of Science ®Google Scholar
• Talaat KR, Luke CJ, Khurana S, et al. A live attenuated H5N1 vaccine induces long-term immunity in the absence of a primary antibody response. J Infect Dis 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Bentebibel SE, Lopez S, Obermoser G, et al. Induction of ICOS+CXCR3+CXCR5+ TH cells correlates with antibody responses to influenza vaccination. Sci Transl Med 2013;5(176):176ra132
   Web of Science ®Google Scholar
• Gurwith M, Lock M, Taylor EM, et al. Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study. Lancet Infect Dis 2013;13(3):238-50
   PubMed Web of Science ®Google Scholar
• Bright RA, Carter DM, Crevar CJ, et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One 2008;3(1):e1501
   PubMed Web of Science ®Google Scholar
• Khurana S, Wu J, Verma N, et al. H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans. J Virol 2011;85(21):10945-54
   PubMed Web of Science ®Google Scholar
• Landry N, Ward BJ, Trepanier S, et al. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS One 2010;5(12):e15559
   PubMed Web of Science ®Google Scholar
• Antrobus RD, Berthoud TK, Mullarkey CE, et al. Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses. Mol Ther 2014;22(1):233-8
   PubMed Web of Science ®Google Scholar
• Antrobus RD, Coughlan L, Berthoud TK, et al. Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved influenza A antigens. Mol Ther 2014;22(3):668-74
   PubMed Web of Science ®Google Scholar
• Lillie PJ, Berthoud TK, Powell TJ, et al. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. Clin Infect Dis 2012;55(1):19-25
   PubMed Web of Science ®Google Scholar
• Powell TJ, Peng Y, Berthoud TK, et al. Examination of influenza specific T cell responses after influenza virus challenge in individuals vaccinated with MVA-NP+M1 vaccine. PLoS One 2013;8(5):e62778
   PubMed Web of Science ®Google Scholar
• Mossler C, Groiss F, Wolzt M, et al. Phase I/II trial of a replication-deficient trivalent influenza virus vaccine lacking NS1. Vaccine 2013;31(52):6194-200
   PubMed Web of Science ®Google Scholar
• Romanova J, Krenn BM, Wolschek M, et al. Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine. PLoS One 2009;4(6):e5984
   PubMed Web of Science ®Google Scholar
• Wacheck V, Egorov A, Groiss F, et al. A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1. J Infect Dis 2010;201(3):354-62
   PubMed Web of Science ®Google Scholar
• Wressnigg N, Voss D, Wolff T, et al. Development of a live-attenuated influenza B DeltaNS1 intranasal vaccine candidate. Vaccine 2009;27(21):2851-7
   PubMed Web of Science ®Google Scholar
• Hatta Y, Hatta M, Bilsel P, et al. An M2 cytoplasmic tail mutant as a live attenuated influenza vaccine against pandemic (H1N1). 2009 influenza virus. Vaccine 2011;29(12):2308-12
   PubMed Web of Science ®Google Scholar
• Watanabe T, Watanabe S, Kim JH, et al. Novel approach to the development of effective H5N1 influenza A virus vaccines: use of M2 cytoplasmic tail mutants. J Virol 2008;82(5):2486-92
   PubMed Web of Science ®Google Scholar
• Powell TJ, Silk JD, Sharps J, et al. Pseudotyped influenza A virus as a vaccine for the induction of heterotypic immunity. J Virol 2012;86(24):13397-406
   PubMed Web of Science ®Google Scholar